Zhang Lei, Jiang Yuqi, Xue Chaofan, Chen Huiyong, Zhang Yongchun
Radiation Oncology, Qingdao University, Qingdao, China.
Department of Oncology Hematology, Peoples Hospital of Qingdao West Coast New Area, Qingdao, China.
Ann Transl Med. 2022 Feb;10(4):239. doi: 10.21037/atm-22-67.
Cervical adenocarcinoma belongs to an invasive subtype of cervical carcinoma, presenting poorly prognostic status. Chemotherapy treatment for recurrent cervical carcinoma are thought to be limited and supposed to be noncurative. Because of the poor prognosis of patients with recurrent cervical carcinoma, however, the benefits of second-line chemotherapy have not yet reached a consensus. Immunotherapy is a split-new tactic of overwhelming carcinomas that relies on the instinct of the immune system to recognize and directly kill neoplasm cells. Here, we reported a 55-year-old female patient with clinical stage IVB cervical adenocarcinoma. The patient received four cycles of systematic therapy, with the regimen of docetaxel plus carboplatin in combined with bevacizumab anti-vascular therapy. The progressive disease (PD) was assessed by imaging evaluation and PD was confirmed once more after four cycles of chemotherapy of albumin paclitaxel plus cisplatin. The patient exhibited a good response during the twelve-cycle of immunotherapy of Camrelizumab, whereas PD was observed upon termination of her immunotherapy. This case with the treatment of PD-1 inhibitor Camrelizumab exhibits a good curative effect and tolerable adverse reactions. In addition, some clinical markers and biomarkers expression levels can be served as the predictors of the effect of anti-PD-1 immunotherapy.
宫颈腺癌属于宫颈癌的一种浸润性亚型，预后较差。复发性宫颈癌的化疗治疗被认为是有限的，且被认为无法治愈。然而，由于复发性宫颈癌患者预后较差，二线化疗的益处尚未达成共识。免疫疗法是一种全新的治疗癌症的策略，它依靠免疫系统识别并直接杀死肿瘤细胞的本能。在此，我们报告了一名55岁的IVB期宫颈腺癌女性患者。该患者接受了四个周期的系统治疗，方案为多西他赛联合卡铂并联合贝伐单抗抗血管治疗。通过影像学评估评估疾病进展（PD），在白蛋白紫杉醇联合顺铂化疗四个周期后再次确认PD。该患者在接受十二个周期的卡瑞利珠单抗免疫治疗期间表现出良好反应，但在免疫治疗结束时观察到疾病进展。该例使用PD-1抑制剂卡瑞利珠单抗治疗显示出良好的疗效和可耐受的不良反应。此外，一些临床标志物和生物标志物的表达水平可作为抗PD-1免疫治疗效果的预测指标。
